Armenia Medical Device Periodic Safety Reports: Class 3 and Implantable Class 2b/3 Devices

1. Key takeaways

The scope of the periodic safety report obligation is precisely delimited: Class 3 medical devices and Class 2b and Class 3 devices implanted into the human body must be covered by periodic safety and clinical effectiveness reports during the post-market phase, submitted by the manufacturer or its authorized representative. The GRZAN conclusion: this is not a duty for all products; the two key words for determining applicability are risk class (Class 3) and implantability (implanted Class 2b/3). Products outside this scope remain subject to routine adverse event (incident) reporting only, and expanding the obligation unnecessarily is one of the most frequent and most costly errors observed in practice, since periodic reports demand continuous clinical data work that low-risk portfolios cannot justify.

2. Legal basis

3. Expert insights

Insight 1: Article 4(b) is worded as a union of two sets. The article provides that surveillance is based on the analysis of periodic reports on the safety and clinical effectiveness of Class 3 devices by potential use risk and Class 2b and Class 3 devices implanted into the human body during the post-market phase; such reports come from the medical device manufacturer or its authorized representative. GRZAN note: the two sets are all Class 3 devices (whether implantable or not) and implanted Class 2b and Class 3 devices; the combined obligation scope is therefore all Class 3 plus implantable Class 2b.

Insight 2: Non-implantable Class 2b and lower-risk products are outside the scope. GRZAN note: by reading the provision in reverse, Class 1 and Class 2a devices (whether implantable or not) and non-implantable Class 2b devices fall outside the periodic reporting obligation, but they remain subject to routine adverse event (incident) reporting under Article 4(a) and to the post-market data system duty under Article 4(c). A common error is to extend the periodic reporting duty to the entire product portfolio, creating unnecessary cost, both in report preparation and in clinical effectiveness data collection that the excluded products never required.

Insight 3: Submission may be made by the authorized representative. The provision explicitly states that the reports come from the manufacturer or its authorized representative. GRZAN note: combined with the elevated status of the authorized representative under Decision No. 43 of 2026, manufacturers located outside the Union should state in the authorization letter a separate duty for the preparation and submission of post-market periodic reports, and agree on data provision and the allocation of responsibilities.

Insight 4: The report covers two dimensions, safety and clinical effectiveness. Unlike routine reports that focus on adverse events, the periodic report must cover both safety and clinical effectiveness. GRZAN note: the clinical effectiveness dimension means that clinical use outcomes, literature and comparison data on similar devices must be collected continuously; this work should be planned in advance as a continuation of the pre-market clinical evaluation (practical estimate: the specific reporting cycle and template should be confirmed against what the competent authority publishes).

Insight 5: The reports enter the unified information flow. The general process of the unified information database implemented by Board Order No. 177 of 2018-11-12 covers the formation, maintenance and use of monitoring data. GRZAN note: the final destination of periodic reports is the Union-level unified information database; fields should be organized according to the database standard during preparation, so that data collected once can be reused across registration maintenance and inspection responses without reformatting (practical estimate).

4. Practical recommendations

1. Determine the obligation scope first: assess model by model whether periodic reporting applies, using the scope of all Class 3 plus implantable Class 2b/3, and issue a determination list.
2. Do not over-apply: do not prepare periodic reports for non-implantable Class 2b devices or Class 1 and Class 2a products, to avoid unnecessary cost.
3. List the reporting duty separately in the authorization letter: state the duties for preparing and submitting periodic reports, the duty to provide data, and the allocation of responsibilities.
4. Plan two-dimensional data collection in advance: include continuous clinical effectiveness data collection in the continuation plan of the pre-market clinical evaluation.
5. Organize fields by the database standard: keep report fields consistent with the unified information database to reduce conversion cost.

5. Verification checklist

1. □ Periodic reporting obligations determined model by model under the scope of all Class 3 plus implantable Class 2b/3.
2. □ Confirmed that non-implantable Class 2b and Class 1 and Class 2a products are not subject to periodic reports.
3. □ The duties of preparing and submitting periodic reports are stated separately in the authorization letter.
4. □ A mechanism for continuous collection of safety and clinical effectiveness data has been planned.
5. □ Confirmed that the submitter of the reports is the manufacturer or its authorized representative.
6. □ Report fields organized according to the unified information database standard (practical estimate noted).
7. □ Reporting cycle and template confirmed against the competent authority’s position (practical estimate).

Regulatory information verified as of October 30, 2026.

About GRZAN: GRZAN supports medical device manufacturers entering Armenia and the Eurasian Economic Union with regulatory registration, quality management systems, post-market surveillance and import clearance compliance. For inquiries, contact info@grzanglobal.com.